IR Contact

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

Investor contact: 
Alex Lobo
Stern Investor Relations 

Media contact:
Sarah Thailing
Senior Director, Corporate Communications and IR
Poseida Therapeutics, Inc.